Fig. 5: Correlation analysis of ECT2 and TACC3 expression levels with invasiveness and prognosis in patients with CXPA.

A Expression levels of ECT2 are illustrated in UMAP plots from eight epithelial cell clusters. B Expression levels of TACC3 illustrated in UMAP plots from eight epithelial cell clusters. C IHC analysis of the ECT2 expression levels (Scale bar = 20 μm) in CXPA and PA, as well as corresponding H&E staining results. D IHC analysis of the TACC3 expression levels (Scale bar = 20 μm) and the H&E staining results in CXPA and PA. The scoring system of ECT2 and TACC3 expression was as follows: low expression (score < 3), moderate expression (3 ≤ score < 6), and high expression (score ≥ 6). E Comparison of ECT2 and TACC3 expression in CXPA (n = 100) and PA (n = 29) patients. F Comparison of ECT2 and TACC3 expression in patients with WICXPA (n = 50), MICXPA, and ICCXPA (n = 50, Mann–Whitney U-test). G Comparison of ECT2 and TACC3 expression in patients with WICXPA (n = 50), MICXPA, and ICCXPA patients (n = 50, Fisher’s exact test). The thick line indicates the median value. The bottom and top of the boxes represent the 25th and 75th percentiles (interquartile range) and extend through the whiskers to 1.5 times the interquartile range. H Kaplan–Meier curves for OS based on ECT2 expression levels (log-rank test, P > 0.05) in WICXPA (n = 50). I Kaplan–Meier curves for OS based on TACC3 expression levels (log-rank test, P < 0.05) in WICXPA (n = 50). J Univariate and multivariate logistic regression analyses assessing the predictive value of biomarkers (ECT2 and TACC3 expression) for the invasive degree of CXPA. K Univariate and multivariate logistic regression analyses assessing the prognostic value of biomarkers (ECT2 and TACC3 expression) in patients with WICXPA. OR Odds Ratio.